Immutep (IMMP) Total Non-Current Liabilities (2011 - 2025)
Immutep's (IMMP) quarterly Total Non-Current Liabilities came in at $847643.0 in Q4 2025, up 101.17% YoY from $421355.4 in Q4 2024, and up 124.62% on a QoQ basis from $377360.5 in Q2 2025.
Immutep (IMMP) Total Non-Current Liabilities (2011 - 2025) Analysis & Trends
Immutep (IMMP) has 15 years of Total Non-Current Liabilities data on file, last reported at $847643.0 in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 101.17% year-over-year to $847643.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $847643.0 (up 101.17% YoY) and the FY2025 annual result came in at $377360.5, down 63.56% from the prior year.
- Total Non-Current Liabilities advanced to $847643.0 in Q4 2025, from $377360.5 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $2.6 million in Q2 2021 to a low of $377360.5 in Q2 2025.
- A 5-year average of $1.2 million and a median of $941128.1 in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities plunged 75.64% — and 2025, when it jumped 101.17%.
- Tracing IMMP's Total Non-Current Liabilities over 5 years: stood at $2.5 million in 2021, then sank by 75.64% to $616473.7 in 2022, then surged by 67.83% to $1.0 million in 2023, then plunged by 59.27% to $421355.4 in 2024, then jumped by 101.17% to $847643.0 in 2025.
- The last three Total Non-Current Liabilities figures came in at $847643.0 (Q4 2025), $377360.5 (Q2 2025), and $421355.4 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 9.32 Bn |
| 10 | Immutep | 56.62 Mn | -8.47 Mn | - | 847,642.96 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 847,642.96 |
| Jun 30, 2025 | 377,360.54 |
| Dec 31, 2024 | 421,355.35 |
| Jun 30, 2024 | 1.04 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Jun 30, 2023 | 807,041.90 |
| Dec 31, 2022 | 616,473.70 |
| Jun 30, 2022 | 1.20 Mn |
| Dec 31, 2021 | 2.53 Mn |
| Jun 30, 2021 | 2.63 Mn |
| Dec 31, 2020 | 7.72 Mn |
| Jun 30, 2020 | 6.51 Mn |
| Dec 31, 2019 | 7.49 Mn |
| Jun 30, 2019 | 7.60 Mn |
| Dec 31, 2018 | 7.59 Mn |
| Jun 30, 2018 | 7.29 Mn |
| Jun 30, 2017 | 4.36 Mn |
| Mar 31, 2017 | 4.27 Mn |
| Dec 31, 2016 | 23.45 Mn |
| Jun 30, 2016 | 4.30 Mn |